Zydus Cadila has received approval for Emergency Use Authorisation (EUA) from DCGI for its three-dose COVID-19 vaccine ZyCoV-D. It's shown to be 66.6% effective in phase 3 trials and has become sixth COVID-19 vaccine to be approved in India. It's the world's first and India's indigenously-developed DNA-based vaccine for COVID-19 to be administered in those aged 12 years and above.
 

Zydus Cadila has received approval for Emergency Use Authorisation (EUA) from DCGI for its three-dose COVID-19 vaccine ZyCoV-D. It's shown to be 66.6% effective in phase 3 trials and has become sixth COVID-19 vaccine to be approved in India. It's the world's first and India's indigenously-developed DNA-based vaccine for COVID-19 to be administered in those aged 12 years and above.